MAPT and Alzheimer disease: Therefore, we constructed an astrocyte activation PRS and assessed its predictive value for cognitive decline and AD biomarkers (i.e., cerebrospinal fluid [CSF] levels of Aβ1–42, total tau, and p-tau181) in a cohort of 791 elderly individuals.